Skip to main content
All lobbying filings

ARENTFOX SCHIFF LLP

Lobbying for ORGANOGENESIS INC. · Biotech company

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Income
$70,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 4
  • Executive Office of the President (EOP)
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 4
  • HR 5768
    Skin Substitute Access and Payment Reform Act
  • S 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • HR 5304
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
  • S 2587
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
 Lobbying activity 2
Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R. 5304 and S. 2587 (Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2026), regarding reimbursement for chronic wound healing products

Health Issues

Food and Drug Administration policy on chronic wound healing products

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem